Patent office determines UC, Broad Institute patent claims on CRISPR-Cas9 genome editing are separately patentable

The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) today ruled that the inventions claimed in the pending U.S. patent application filed by the Doudna/Charpentier research group and the patents and applications filed by the Broad Institute are separately patentable from one another, thereby moving the Doudna/Charpentier group’s application closer to issuance as a U.S. patent.